Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography Reply
Michael MacManus, Richard Fisher, Bev McClure, John F Seymour
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019
Supported by the Cancer Council of Victoria, with additional funding contributed by the Australasian Leukaemia and Lymphoma Group, Peter MacCallum Cancer Centre, Amgen, and Roche. Roche also supplied the rituximab used in the amended version of the trial. Quality assurance for the trial was supported by a grant from the Australian Federal Department of Health.